Eris Lifesciences Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Amit Bakshi
Chief executive officer
₹48.8m
Total compensation
| CEO salary percentage | 35.9% |
| CEO tenure | 18.1yrs |
| CEO ownership | 42.9% |
| Management average tenure | 8.4yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Analysts Are Updating Their Eris Lifesciences Limited (NSE:ERIS) Estimates After Its Third-Quarter Results
Feb 09
What You Can Learn From Eris Lifesciences Limited's (NSE:ERIS) P/E
Jan 07Here's Why Eris Lifesciences (NSE:ERIS) Can Manage Its Debt Responsibly
Nov 21Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next
Oct 30A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Oct 15Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why
Sep 19Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%
Sep 03Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)
Jul 13Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | n/a | n/a | ₹3b |
| Sep 30 2024 | n/a | n/a | ₹3b |
| Jun 30 2024 | n/a | n/a | ₹4b |
| Mar 31 2024 | ₹49m | ₹17m | ₹4b |
| Dec 31 2023 | n/a | n/a | ₹4b |
| Sep 30 2023 | n/a | n/a | ₹4b |
| Jun 30 2023 | n/a | n/a | ₹4b |
| Mar 31 2023 | ₹49m | ₹17m | ₹4b |
| Dec 31 2022 | n/a | n/a | ₹4b |
| Sep 30 2022 | n/a | n/a | ₹4b |
| Jun 30 2022 | n/a | n/a | ₹4b |
| Mar 31 2022 | ₹46m | ₹26m | ₹4b |
| Dec 31 2021 | n/a | n/a | ₹4b |
| Sep 30 2021 | n/a | n/a | ₹4b |
| Jun 30 2021 | n/a | n/a | ₹4b |
| Mar 31 2021 | ₹27m | ₹27m | ₹4b |
| Dec 31 2020 | n/a | n/a | ₹3b |
| Sep 30 2020 | n/a | n/a | ₹3b |
| Jun 30 2020 | n/a | n/a | ₹3b |
| Mar 31 2020 | ₹49m | ₹18m | ₹3b |
| Dec 31 2019 | n/a | n/a | ₹3b |
| Sep 30 2019 | n/a | n/a | ₹3b |
| Jun 30 2019 | n/a | n/a | ₹3b |
| Mar 31 2019 | ₹49m | ₹18m | ₹3b |
| Dec 31 2018 | n/a | n/a | ₹3b |
| Sep 30 2018 | n/a | n/a | ₹3b |
| Jun 30 2018 | n/a | n/a | ₹3b |
| Mar 31 2018 | ₹49m | ₹11m | ₹3b |
Compensation vs Market: Amit's total compensation ($USD563.08K) is about average for companies of similar size in the Indian market ($USD515.08K).
Compensation vs Earnings: Amit's compensation has been consistent with company performance over the past year.
CEO
Amit Bakshi (49 yo)
18.1yrs
Tenure
₹48,776,648
Compensation
Mr. Amit Indubhushan Bakshi serves as Chairman and Managing Director at Eris Lifesciences Limited. Mr. Bakshi has an extensive experience of Indian Pharmaceutical industry and handles Strategic Management...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | no data | ₹48.78m | 42.85% ₹ 74.6b | |
| Chief Financial Officer | 8.4yrs | ₹18.01m | no data | |
| Executive Director & COO | 3.8yrs | ₹44.85m | no data | |
| President of Sales & Marketing | no data | ₹22.05m | no data | |
| Executive Director | no data | ₹12.40m | 4.36% ₹ 7.6b | |
| Whole Time Director | no data | ₹6.99m | 3.28% ₹ 5.7b | |
| Senior Vice President | no data | ₹13.72m | no data | |
| Compliance Officer & Company Secretary | 8.4yrs | no data | no data | |
| President Medical | no data | ₹12.31m | no data | |
| Vice President | no data | ₹12.36m | no data | |
| Vice President | no data | ₹13.30m | no data | |
| Vice President | no data | ₹15.08m | no data |
8.4yrs
Average Tenure
50yo
Average Age
Experienced Management: ERIS's management team is seasoned and experienced (8.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & MD | 18.1yrs | ₹48.78m | 42.85% ₹ 74.6b | |
| Executive Director & COO | 4.2yrs | ₹44.85m | no data | |
| Executive Director | 18.1yrs | ₹12.40m | 4.36% ₹ 7.6b | |
| Whole Time Director | 4.5yrs | ₹6.99m | 3.28% ₹ 5.7b | |
| Independent Non-Executive Director | 6.8yrs | ₹4.13m | no data | |
| Independent Non-Executive Director | 2.6yrs | ₹4.05m | no data | |
| Independent Non-Executive Director | 4.1yrs | ₹4.51m | no data | |
| Independent Non-Executive Director | 4.2yrs | ₹4.65m | no data |
4.3yrs
Average Tenure
50yo
Average Age
Experienced Board: ERIS's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 20:52 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eris Lifesciences Limited is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Harith Ahamed | Avendus Spark |